Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

@article{Stasi2001RituximabCA,
  title={Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.},
  author={Roberto Stasi and Amy E. Pagano and Elisa Stipa and S. Amadori},
  journal={Blood},
  year={2001},
  volume={98 4},
  pages={
          952-7
        }
}
The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) has not been determined. The effectiveness and side effects of this therapeutic modality were investigated in a cohort of 25 individuals with chronic ITP. All patients had ITP that had been resistant to between 2 and 5 different therapeutic regimens, including 8 patients who had already failed splenectomy. Patients were… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 211 CITATIONS

Improving departmental faculty meetings: an analysis of one department's approach.

  • The Journal of pediatrics
  • 2005
VIEW 10 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia.

  • Blood
  • 2016
VIEW 9 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Rituximab in the treatment of autoimmune haematological disorders

St Michael’s
  • 2008
VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2000
2018

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 7 Citations per year over the last 3 years

  • 9% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP) [abstract

MN Saleh, J Gutheil, M Moore
  • Blood
  • 2000

Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura [abstract

A Perotta, TA Sunneberg, J Scott
  • Blood
  • 1999

uximab chimeric anti - CD 20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four - dose treatment program

A Perotta, TA Sunneberg, J Scott
  • J Clin Oncol
  • 1998

Similar Papers

Loading similar papers…